A Phase 1, Open-Label, Positron Emission Tomography Study in Healthy Subjects to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the CNS After Single-Dose Oral Administration
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2017
At a glance
- Drugs TAK 041 (Primary) ; Amphetamines
- Indications Cognition disorders
- Focus Diagnostic use
- Sponsors Takeda
- 29 Jun 2017 Planned End Date changed from 2 Jun 2017 to 23 Aug 2017.
- 29 Jun 2017 Planned primary completion date changed from 2 Jun 2017 to 23 Aug 2017.
- 29 Jun 2017 Status changed from recruiting to active, no longer recruiting.